Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 700Breast Neoplasms 630Neoplasms 583Leukemia, Myeloid, Acute 481Colorectal Neoplasms 457Multiple Myeloma 444Melanoma 426Prostatic Neoplasms 383Neoplasm Metastasis 374Pancreatic Neoplasms 364Recurrence 350Lymphoma 340Ovarian Neoplasms 325Lung Neoplasms 298Lymphoma, Non-Hodgkin 295Leukemia 287Glioblastoma 276Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Stomach Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 235Carcinoma, Hepatocellular 231Squamous Cell Carcinoma of Head and Neck 220Lymphoma, Large B-Cell, Diffuse 217Myelodysplastic Syndromes 212Carcinoma, Renal Cell 210Lymphoma, Follicular 183Head and Neck Neoplasms 172Brain Neoplasms 169Lymphoma, Mantle-Cell 167Triple Negative Breast Neoplasms 166

Interventions

cediranib 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × Thyroid cancer, Hurthle cell × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡